OBJECTIVES: The p1 region of HIV-1 gag contains the frameshift stem-loop, gag-pol transframe and a protease cleavage site that are crucial for viral assembly, replication and infectivity. Identifying and characterizing CD8+ epitopes that are under host immune selection in this region will help in designing effective vaccines for HIV-1. DESIGN: An approach combining bioinformatical analysis and interferon gamma enzyme-linked immunosorbent spot (ELISPOT) assays is used to identify and characterize the epitopes. Potential human leukocyte antigen (HLA)-restricted epitopes were identified by correlating the positively-selected mutations with host HLA alleles. METHODS: ELISPOT analysis with overlapping peptides was used to confirm and characterize the epitopes. RESULTS: Four positively-selected residues were significantly associated with HLA class I alleles, including HLA B*1302 (K4R, P = 0.0008 and I5L, P = 0.0108), A*7401 (S9N, P = 0.0002) and A*30 genotypes (P7S, P = 0.009), suggesting epitopes restricted by these alleles are present in this region. ELISPOT analysis with patient peripheral blood mononuclear cells (PBMCs) identified seven novel epitopes restricted by the 3 alleles. Two types of epitopes were observed in this region based on the ELISPOT responses, Type I: the positively-selected variation does not affect CD8+ T-cell responses; and Type II: the CD8+ T-cell responses are determined by the epitope variants. CONCLUSION: We identified and characterized seven novel CD8+ epitopes in the p1 spacer protein region. Classifying the effects of positively-selected variants on CD8+ T-cell responses will help in designing effective vaccines for HIV-1.
OBJECTIVES: The p1 region of HIV-1gag contains the frameshift stem-loop, gag-pol transframe and a protease cleavage site that are crucial for viral assembly, replication and infectivity. Identifying and characterizing CD8+ epitopes that are under host immune selection in this region will help in designing effective vaccines for HIV-1. DESIGN: An approach combining bioinformatical analysis and interferon gamma enzyme-linked immunosorbent spot (ELISPOT) assays is used to identify and characterize the epitopes. Potential human leukocyte antigen (HLA)-restricted epitopes were identified by correlating the positively-selected mutations with host HLA alleles. METHODS: ELISPOT analysis with overlapping peptides was used to confirm and characterize the epitopes. RESULTS: Four positively-selected residues were significantly associated with HLA class I alleles, including HLA B*1302 (K4R, P = 0.0008 and I5L, P = 0.0108), A*7401 (S9N, P = 0.0002) and A*30 genotypes (P7S, P = 0.009), suggesting epitopes restricted by these alleles are present in this region. ELISPOT analysis with patient peripheral blood mononuclear cells (PBMCs) identified seven novel epitopes restricted by the 3 alleles. Two types of epitopes were observed in this region based on the ELISPOT responses, Type I: the positively-selected variation does not affect CD8+ T-cell responses; and Type II: the CD8+ T-cell responses are determined by the epitope variants. CONCLUSION: We identified and characterized seven novel CD8+ epitopes in the p1 spacer protein region. Classifying the effects of positively-selected variants on CD8+ T-cell responses will help in designing effective vaccines for HIV-1.
Authors: Melissa K Hill; Anna Bellamy-McIntyre; Laura J Vella; Shahan M Campbell; John A Marshall; Gilda Tachedjian; Johnson Mak Journal: Curr HIV Res Date: 2007-01 Impact factor: 1.581
Authors: Lyle R McKinnon; T Blake Ball; Charles Wachihi; Paul J McLaren; Jillian L M Waruk; Xiaojuan Mao; Sue Ramdahin; A Omu Anzala; Jane Kamene; Ma Luo; Keith R Fowke; Francis A Plummer Journal: J Immunol Date: 2007-03-15 Impact factor: 5.422
Authors: Zabrina L Brumme; Iris Tao; Sharon Szeto; Chanson J Brumme; Jonathan M Carlson; Dennison Chan; Carl Kadie; Nicole Frahm; Christian Brander; Bruce Walker; David Heckerman; P Richard Harrigan Journal: AIDS Date: 2008-07-11 Impact factor: 4.177
Authors: L Gudmundsdotter; D Bernasconi; B Hejdeman; E Sandstrom; A Alaeus; K Lidman; B Ensoli; B Wahren; S Buttò Journal: Vaccine Date: 2008-04-22 Impact factor: 3.641
Authors: Christine M Rousseau; Marcus G Daniels; Jonathan M Carlson; Carl Kadie; Hayley Crawford; Andrew Prendergast; Philippa Matthews; Rebecca Payne; Morgane Rolland; Dana N Raugi; Brandon S Maust; Gerald H Learn; David C Nickle; Hoosen Coovadia; Thumbi Ndung'u; Nicole Frahm; Christian Brander; Bruce D Walker; Philip J R Goulder; Tanmoy Bhattacharya; David E Heckerman; Bette T Korber; James I Mullins Journal: J Virol Date: 2008-04-23 Impact factor: 5.103
Authors: Harold O Peters; Mark G Mendoza; Rupert E Capina; Ma Luo; Xiaojuan Mao; Michael Gubbins; Nico J D Nagelkerke; Ian Macarthur; Brent B Sheardown; Joshua Kimani; Charles Wachihi; Subo Thavaneswaran; Francis A Plummer Journal: J Virol Date: 2007-12-05 Impact factor: 5.103
Authors: Julia G Prado; Isobella Honeyborne; Ian Brierley; Maria Carmen Puertas; Javier Martinez-Picado; Philip J R Goulder Journal: J Virol Date: 2008-10-22 Impact factor: 5.103
Authors: Ma Luo; Christina A Daniuk; Tamsir O Diallo; Rupert E Capina; Joshua Kimani; Charles Wachihi; Makubo Kimani; Thomas Bielawny; Trevor Peterson; Mark G R Mendoza; Sandra Kiazyk; T Blake Ball; Francis A Plummer Journal: J Virol Date: 2011-11-09 Impact factor: 5.103
Authors: Christina A Semeniuk; Rupert E Capina; Mark G R Mendoza; Joshua Kimani; T Blake Ball; Ma Luo; Francis A Plummer Journal: J Immunol Methods Date: 2009-11-10 Impact factor: 2.303
Authors: Philippa C Matthews; Emily Adland; Jennifer Listgarten; Alasdair Leslie; Nompumelelo Mkhwanazi; Jonathan M Carlson; Mikkel Harndahl; Anette Stryhn; Rebecca P Payne; Anthony Ogwu; Kuan-Hsiang Gary Huang; John Frater; Paolo Paioni; Henrik Kloverpris; Pieter Jooste; Dominique Goedhals; Cloete van Vuuren; Dewald Steyn; Lynn Riddell; Fabian Chen; Graz Luzzi; Thambiah Balachandran; Thumbi Ndung'u; Søren Buus; Mary Carrington; Roger Shapiro; David Heckerman; Philip J R Goulder Journal: J Immunol Date: 2011-04-15 Impact factor: 5.422